The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
Lixisenatide Lixisenatide (Fig
Orders placed before 2:00 PM EST ship the same business day
Participants were randomly assigned 3:1 to receive AMG 133 or placebo
Numerous studies have found that GLP-1 agonists can be effective for weight loss, blood sugar management, and heart health, especially when combined with diet and lifestyle changes
According to a recent report by Morgan Stanley, the global market for obesity drugs is expected to increase 15-fold by 2030, driven by their expanding use beyond weight loss to address various obesity-related conditions